1. Home
  2. Browse
  3. BrightFocus Foundation
  4. BrightFocus Foundation — Artificial Intelligence-Guided Drug Discovery for Alzheimer's Disease

BrightFocus Foundation

BrightFocus Foundation — Artificial Intelligence-Guided Drug Discovery for Alzheimer's Disease

Deadline
Rolling
Check the funder's page for current deadlines
Award ceiling
$25,000
Awards
Not stated
Posted
Not stated

Official announcement on the funder's site · opens the funder's page. Always confirm dates there.

Summary

Artificial Intelligence-Guided Drug Discovery for Alzheimer's Disease BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma. Search Translation EN ES FR DE ID About the Disease What is Alzheimer’s Disease?…

Preparing an application?

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
Start with PlusSign in

Cancel any time. Browsing stays free.

Subjects

More from BrightFocus Foundation

Open now with at least two weeks to apply, soonest deadline first.

BrightFocus Foundation — Hidden RNA Alterations by Jumping Genes in Alzheimer's Disease

BrightFocus Foundation

$25k
Rolling

BrightFocus Foundation — Spatial Responses to Elevated Pressure in the Human Optic Nerve Head

BrightFocus Foundation

$150k
Rolling

BrightFocus Foundation — Artificial Intelligence-Guided Drug Discovery for Alzheimer's Disease

BrightFocus Foundation

$25k
Rolling

BrightFocus Foundation — Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening

BrightFocus Foundation

$150k
Rolling

Everything open from BrightFocus Foundation

Related by subject

Open opportunities sharing the most subjects with this one (Alzheimer's, Data science and AI), with at least two weeks to apply.

INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)

RFA-OD-27-005National Institutes of Health3 review criteria on fileagency framework

—

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

PAR-25-226National Institutes of Health3 review criteria on fileagency framework

—

DoW Traumatic Brain Injury and Psychological Health, Health Services Research Award

HT942526TBIPHRPHSRADefense Health Agency Contracting Activity - DHACAReview criteria on file

—

Everything open tagged Alzheimer's

Hiring in this research area now

All neuroscience jobs

Source record: https://www.brightfocus.org/grant/fibril-specific-ai-drug-design-to-identify-tau-aggregation-inhibitors-in-alzheimers-disease/Via the funder's site. Last checked against the source . Always confirm dates with the funder.